RxDoctor Payments Data

Patrick Gomella, MD

Urology · Abington, PANPI 1093058315

Payments from drug & device makers

$4,557in general payments, 2019–2025

Across 57 payments — averaging $79.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$3K
  • Teleflex LLC$345
  • EDAP Technomed Inc$110
  • Convatec Inc.$96
  • Boston Scientific$90
  • Sumitomo Pharma America, Inc.$86
  • plus $526 from 14 others

What the payments were for

  • Travel & lodging$1,73038%
  • Food & beverage$2,82762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,557 in reported general payments places this provider in the 65th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$97,728
Medicare patients
401
Services billed
905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron19$13,293
MyrbetriqMirabegron16$10,826
Tamsulosin Hcl158$3,383
Trospium Chloride ErTrospium Chloride17$2,147
Finasteride103$2,028
Solifenacin Succinate16$1,286
Alfuzosin Hcl ErAlfuzosin Hcl40$942
Oxybutynin Chloride ErOxybutynin Chloride37$819
Tadalafil11$353
Ciprofloxacin Hcl33$50

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$86$13,29319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 596 urology providers in Pennsylvania.

Other urology in Abington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →